Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 701–800 of 1,017
The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease
Rhee, E., Byrne, C. D., & Sung, K. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000315 · Cited by 54
Sarin, H. V., Lee, J. H., Jauhiainen, M., Joensuu, A., Borodulin, K., Männistö, S., Jin, Z., Terwilliger, J. D., Isola, V., Ahtiainen, J. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40107-6 · Cited by 67
Did we abandon probucol too soon?
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000199 · Cited by 56
HDL-cholesterol: Is it really good?
Santos‐Gallego, C. G., Ibáñez, B., & Badimón, J. J. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.04.020 · Cited by 66
Dullaart, R. P. F., & Sluiter, W. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.6.747 · Cited by 54
Taylor, A., Sullenberger, L., Lee, H., Lee, J., & Grace, K. A. (2008) · The Physician and Sportsmedicine · doi:10.3810/psm.2008.12.22 · Cited by 51
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 60
Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
Masana, L., Plana, N., Andreychuk, N., & Ibarretxe, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106738 · Cited by 59
Chen, J., Li, Y., Zhang, Y., Wang, Y., Zhou, Y., Geng, T., Liu, G., Pan, A., & Liao, Y.-F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155817 · Cited by 56
Charles‐Schoeman, C., Lee, Y. Y., Shahbazian, A., Gorn, A. H., FitzGerald, J. D., Ranganath, V. K., Taylor, M. B., Ragavendra, N., McMahon, M. A., Elashoff, D. A., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38118 · Cited by 51
Krishna, R., Garg, A., Panebianco, D. L., Côté, J., Bergman, A. J., Hoydonck, P. V., Laethem, T., Dyck, K. V., Chen, J., Chavez-Eng, C. M., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03465.x · Cited by 51
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 53
Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering
Pikuleva, I. A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.11.1403 · Cited by 52
“The reduction of LDLC is variable and could be 10–20% in individuals with elevated LDL-C [33].”
BackgroundInfluentialHDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity
Borja, M. S., Ng, K. F., Irwin, A., Hong, J., Wu, X., Isquith, D., Zhao, X.-Q., Prazen, B., Gildengorin, V., Oda, M. N., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m059865 · Cited by 50
Time to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 52
“mortality (torcetrapib) [8] or lack of CVD risk reduction (dalcetrapib [9] and evacetrapib [10]).”
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 57
Longitudinal Ultrasound Evaluation of Carotid Atherosclerosis in One, Two and Three Dimensions
Mallett, C. L., House, A. A., Spence, J. D., Fenster, A., & Párraga, G. (2008) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2008.09.008 · Cited by 51
Stroes, E. S. G., Kastelein, J. J. P., Benardeau, A. M., Kuhlmann, O., Blum, D., Campos, L. A., Clerc, R. G., & Niesor, E. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00460.x · Cited by 50
“…The British Pharmacological Society All rights reserved 0007-1188/09 www.brjpharmacol.org Off-target effects on blood pressure and plasma aldosterone, indicating activation of the renin-angiotensin-aldosterone system (RAAS), may have contributed to the toxicity of torcetrapib (Barter et al., 2007).”
BackgroundResultInfluentialSelf-citation2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
Zeitouni, M., Sabouret, P. F., Kernéis, M., Silvain, J., Collet, J., Bruckert, É., & Montalescot, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa077 · Cited by 61
Human genetics as a foundation for innovative drug development
Kamb, A., Harper, S., & Stefánsson, K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2732 · Cited by 49
Dávalos, A., & Fernandez-Hernando, C. F. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.02.005 · Cited by 56
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript 2.4 HDL and reverse cholesterol transport High circulating LDL cholesterol (LDL-C) and low HDL cholesterol (HDL-C) are important risk factors for coronary artery disease (CAD).”
BackgroundInfluentialLipid transfer proteins: Past, present and perspectives
Quintão, E. C. R., & Cazita, P. M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.002 · Cited by 52
High-Density Lipoprotein Functionality in Coronary Artery Disease
Kosmas, C. E., Christodoulidis, G., Cheng, J.-W., Lerakis, S., & Vittorio, T. J. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000231 · Cited by 52
“Based on the above findings, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial was designed to assess the hypothesis that torcetrapib would decrease cardiovascular events in high-risk populations.(14) Despite a 72.”
ResultBell, S., Mehta, G., Moore, K. P., & Britton, A. R. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12544 · Cited by 55
High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
Choi, H. Y., Hafiane, A., Schwertani, A. G., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.012 · Cited by 59
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
“Torcetrapib ILLUMINATE Pfizer 15067 III Death from CAD, nonfatal MI, stroke, or hospitalization for unstable angina 550 days [median follow-up] Torcetrapib increased HDL-C, decreased LDL-C, increased blood pressure, and CV mortality and morbidity [52].”
BackgroundSelf-citationSerum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study
Brahimaj, A., Ligthart, S., Ikram, M. A., Hofman, A., Franco, O. H., Sijbrands, E. J. G., Kavousi, M., & Dehghan, A. (2016) · Diabetes Care · doi:10.2337/dc16-1295 · Cited by 55
Furuhashi, M., Ogura, M., Matsumoto, M., Yuda, S., Muranaka, A., Kawamukai, M., Omori, A., Tanaka, M., Moniwa, N., Ohnishi, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00177-w · Cited by 55
Nissen, S. E., Pillai, S. G., Nicholls, S. J., Wolski, K., Riesmeyer, J. S., Weerakkody, G. J., Foster, W. M., McErlean, E. S., Li, L., Bhatnagar, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0569 · Cited by 50
HDL flux is higher in patients with nonalcoholic fatty liver disease
McCullough, A. J., Previs, S. F., Dasarathy, J., Lee, K., Ösme, A., Kim, C., Ilchenko, S., Lorkowski, S. W., Smith, J. D., Dasarathy, S., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2019 · Cited by 53
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 64
Sunshine, S. B., Dallabrida, S. M., Durand, E. M., Ismail, N. S., Bazinet, L. F., Birsner, A. E., Sohn, R. L., Ikeda, S., Pu, W. T., Kulke, M. H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203275109 · Cited by 49
“This finding is concerning, given that changes in BP of as little as 5 mm Hg can significantly impact mortality (20).”
BackgroundmRNA Transcript Diversity Creates New Opportunities for Pharmacological Intervention
Barrie, E. S., Smith, R. M., Sanford, J. C., & Sadée, W. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076604 · Cited by 54
Talayero, B., Wang, L., Furtado, J., Carey, V. J., Bray, G. A., & Sacks, F. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m042333 · Cited by 49
Advances in the Understanding of Plaque Composition and Treatment Options
Tomey, M. I., Narula, J., & Kovacic, J. C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.042 · Cited by 56
Stanton, K., Kienzle, V., Dinnes, D. L. M., Kotchetkov, I., Jessup, W., Kritharides, L., Celermajer, D. S., & Rye, K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023386 · Cited by 62
“9 In light of this, attention has shifted away from using HDL-C to reduce CVD risk toward strategies with the potential to improve HDL function.”
Nicotinic acid and the prevention of coronary artery disease
Digby, J. E., Lee, J., & Choudhury, R. P. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832d3b9d · Cited by 48
Nordestgaard, B. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283307bfe · Cited by 48
van de Woestijne, A. P., van der Graaf, Y., Liem, A. H., Cramer, M. J., Westerink, J., & Visseren, F. L. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.101 · Cited by 47
“Although a Mendelian randomization study indicated that HDL-C as such may not be a causal factor in vascular disease (31), and previous trials with CETP inhibitors (16,32) or niacin (17–19) to increase HDL-C in addition to intensive statin treatment showed no reduction of cardiovascular events, the new CETP inhibitors…”
BackgroundHDL Metabolism and CETP Inhibition
Barkowski, R. S., & Frishman, W. H. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816a3b60 · Cited by 51
“However, an observed reduction in potassium and an increase in sodium, bicarbonate and aldosterone levels with torcetrapib suggests mineralocorticoid excess.(68) Recently Nissen et al(69) reported on the results of an independent parallel study called the Investigation of Lipid Level Management Using Coronary Ultrasou…”
BackgroundNew CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism
Miyosawa, K., Watanabe, Y., Murakami, K., Murakami, T., Shibata, H., Iwashita, M., Yamazaki, H., Yamazaki, K., Ohgiya, T., Shibuya, K., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00528.2014 · Cited by 49
“To investigate the potential effect of K-312 on blood pressure (2, 18), we measured arterial blood pressure in Sprague-Dawley rats.”
BackgroundMethodFarràs, M., Castañer, O., Martín‐Peláez, S., Hernáez, Á., Schröder, H., Subirana, I., Muñoz‐Aguayo, D., Gaixas, S., de la Torre, R., Farré, M., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500030 · Cited by 59
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Cao, J., Nomura, S. O., Steffen, B. T., Guan, W., Remaley, A. T., Karger, A. B., Ouyang, P., Michos, E. D., & Tsai, M. Y. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.005 · Cited by 48
Cardiovascular Disease in Diabetes
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb04 · Cited by 56
Bhatt, D. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.002 · Cited by 48
Niacin and HDL Cholesterol — Time to Face Facts
Lloyd‐Jones, D. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1406410 · Cited by 48
The role of high-density lipoproteins in the regulation of angiogenesis
Tan, J. T. M., Ng, M., & Bursill, C. A. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv104 · Cited by 50
Proteomic Strategies in the Search of New Biomarkers in Atherothrombosis
Tuñón, J., Martı́n-Ventura, J. L., Blanco‐Colio, L. M., Lorenzo, Ó., López, J. A., & Egido, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.036 · Cited by 47
“However, torcetrapib, a drug that increases HDL plasma levels, enhances mortality (17).”
BackgroundHovingh, G. K., Rader, D. J., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000161 · Cited by 54
“Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE; NCT00134264) study was stopped prematurely because of deleterious effects on CVD outcome of torcetrapib, despite a 70% increase in HDL-C and a 25% reduction in LDL-C levels [46] This unexpected deleterious outcome w…”
BackgroundSmall high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease
Krychtiuk, K. A., Kastl, S., Pfaffenberger, S., Pongratz, T., Hofbauer, S. L., Wonnerth, A., Katsaros, K. M., Goliasch, G., Gašpar, Ľ., Huber, K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.015 · Cited by 51
Jensen, M. K., Rimm, E. B., Rader, D., Schmidt, E. B., Sørensen, T. I. A., Vogel, U., Overvad, K., & Mukamal, K. J. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.10.008 · Cited by 47
“However, trials of promising HDL-C–increasing drugs such as cholesterol ester transfer protein inhibitors have been consistently negative to date.(39,40) Given this, other targets have become more attractive, and indeed clinical trials targeting LPL with specific activators (NO1886) or with gene therapy using the S447…”
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 58
“Unfortunately, the first of these to be tested, torcetrapib, proved to be toxic”
BackgroundCurrent concept of reverse cholesterol transport and novel strategy for atheroprotection
Ono, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.014 · Cited by 54
“The recent negative results obtained by the ILLUMINATE [6] and AIM-HIGH trials [7]”
ResultCorsetti, J. P., Ryan, D., Rainwater, D. L., Moss, A. J., Zareba, W., & Sparks, C. E. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207977 · Cited by 47
Nidorf, S. M., Eikelboom, J. W., & Thompson, P. L. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413499972 · Cited by 49
“When trialed in combination with statins in human trials, however, they had no effect on plaque size and were associated with a nonsignificant increase in mortality.(44) As a result, CETP inhibitors are no longer being developed for the secondary prevention of cardiovascular disease.”
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
Salazar, J. J., Olivar, L. C., Ramos, E., Chávez-Castillo, M., Rojas, J., & Bermúdez, V. (2015) · Cholesterol · doi:10.1155/2015/296417 · Cited by 55
“health: certain hereditary syndromes featuring scant HDL-C levels have been shown not to display early atherosclerosis [13–15]; and very high levels of this lipoprotein do not appear to grant additional benefits [16].”
BackgroundMethodNovel anti-inflammatory strategies in atherosclerosis
van der Valk, F. M., van Wijk, D. F., & Stroes, E. S. G. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283587543 · Cited by 48
Chalmers, A. D., Bursill, C. A., & Myerscough, M. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187674 · Cited by 47
“disappointing [4–7].”
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L., Fogacci, F., & Cicero, A. F. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 47
“4 mm Hg), a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone [20].”
BackgroundBonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 54
“9% decrease in LDL-C, and a 9% decrease in TG levels [113].”
BackgroundRaising HDL cholesterol in women
Merchant, N. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5110 · Cited by 57
“alone in a large-scale clinical trial involving 15,067 male and female subjects deemed to be at high cardiac risk.(117)”
Structural and functional changes in HDL with low grade and chronic inflammation
O'Neill, F., Riwanto, M., Charakida, M., Colin, S., Manz, J., McLoughlin, E., Khan, T. A., Klein, N. J., Kay, C. W. M., Patel, K., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.058 · Cited by 50
“While off-target effects and insufficient increase in circulating HDL level may account for the lack of benefit from Torcetrapib, Dalcetrapib and Niacin, the biological function of HDL and the inflammatory status of the population may be of great importance in determining the clinical benefits of HDL elevating therapi…”
BackgroundNicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.002 · Cited by 48
Self-citationPhenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity
Milman, S., Atzmon, G., Crandall, J. P., & Barzilai, N. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111666131219101551 · Cited by 49
“In fact, a trial of the CETP inhibitor torcetrapib was halted prematurely due to an increased number of cardiovascular and all cause mortality events associated with its use[66], despite a significant elevation in HDL cholesterol levels and particle size[67]; whereas, a trial of dalcetrapib was stopped early secondary…”
BackgroundConnelly, M. A., Parry, T. J., Giardino, E. C., Huang, Z., Cheung, W.-M., Chen, C., Cools, F. J. S., van der Linde, H. J., Gallacher, D. J., Kuo, G., et al. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181cf03cb · Cited by 51
Ruiz-Núñez, B., Kuipers, R. S., Luxwolda, M. F., Graaf, D. J. D., Breeuwsma, B. B., Dijck-Brouwer, J., & Muskiet, F. A. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.11.004 · Cited by 52
“That the relation between serum lipoprotein cholesterol concentrations and CAD risk is indeed not as simple as until recently assumed has become strikingly illustrated by the failures of cholesteryl ester transfer protein inhibitors to reduce CAD risk despite their ability to greatly increase HDLC [22,23].”
BackgroundBrulhart‐Meynet, M., Braunersreuther, V., Brinck, J. W., Montecucco, F., Prost, J., Thomas, A., Galan, K., Pelli, G., Pedretti, S., Vuilleumier, N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119664 · Cited by 51
“The recent disappointing results of clinical trials that used HDL-cholesterol raising drugs to reduce vascular risk [14] have re-opened the debate about how to exploit the protective influence apparently mediated by HDL.”
ResultHarbaum, L., Ghataorhe, P., Wharton, J., Jiménez, B., Howard, L., Gibbs, J. S. R., Nicholson, J. K., Rhodes, C. J., & Wilkins, M. R. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-212144 · Cited by 48
Squalene monooxygenase - a target for hypercholesterolemic therapy
Belter, A., Skupińska, M., Giel-Pietraszuk, M., Grabarkiewicz, T., Rychlewski, L., & Barciszewski, J. (2011) · Biological Chemistry · doi:10.1515/bc.2011.195 · Cited by 53
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
“The potent HDL-elevating drugs cholesteryl ester transfer protein (CETP) inhibitors have not been found to reduce cardiovascular disease; the first CETP inhibitor tested actually showed increased mortality in the treated group, probably due to off-target effects [35], and a study with another CETP inhibitor was premat…”
BackgroundRationale for cholesteryl ester transfer protein inhibition
Hewing, B., & Fisher, E. A. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328353ef1d · Cited by 46
“The torcetrapib group had a mean increase of systolic blood pressure of 5 mmHg, increase in serum aldosterone, reduction of serum potassium and an increase in serum bicarbonate and sodium levels [12].”
BackgroundSecondary Prevention Strategy of Cardiovascular Disease Using Endothelial Function Testing
Matsuzawa, Y., Guddeti, R. R., Kwon, T., Lerman, L. O., & Lerman, A. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0068 · Cited by 46
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006359 · Cited by 45
“The cholesterol ester transport protein inhibitors provide an attractive new mechanism for increasing HDL-C and reducing LDL-C but the failure in Phase III trials of torcetrapib with off-target effects including increase in blood pressure [78], and of dalcetrapib in the dal-OUTCOMES study for futility are disappointin…”
BackgroundGómez, M. C. G., Bianchi, M. L., de la Fuente, D., Badimón, L., Padró, T., Corbella, E., & Pintó, X. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.304 · Cited by 50
Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment
Harada, A., Toh, R., Murakami, K., Kiriyama, M., Yoshikawa, K., Miwa, K., Kubo, T., Irino, Y., Mori, K., Tanaka, N. K., et al. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.022913 · Cited by 47
Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention
Ossoli, A., Pavanello, C., Giorgio, E., Calabresi, L., & Gomaraschi, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180316115726 · Cited by 49
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis
Rodríguez, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00902-3 · Cited by 48
Familial Hypercholesterolemia: Present and Future Management
Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 50
“These findings are in line with the ILLUMINATE trial, which was prematurely terminated because of unexpected increased mortality and morbidity in patients treated with atorvastatin combined with torcetrapib [72].”
BackgroundResultSelf-citationSerban, M.-C., Banach, M., & Mikhailidis, D. P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 44
“development of this drug.[63] The development and evaluation of the second CETP inhibitor, dalcetrapib,”
BackgroundInfluentialHDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
Chyu, K., & Shah, P. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00187 · Cited by 47
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 46
The failure of torcetrapib: what have we learned?
Joy, T. R., & Hegele, R. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.248 · Cited by 44
“…of ILLUMINATE revealed increased aldosterone levels in the torcetrapib arm, although a direct comparison of the mean values was not possible due to only 87–88% of samples being analysed and 53–57% of samples having aldosterone levels below the lower limit of quantification (Barter et al., 2007).”
BackgroundResultInfluentialManagement of dyslipidemia in people with type 2 diabetes mellitus
Dunn, F. L. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9132-6 · Cited by 46
“CETP inhibitors also increase HDL-C [87], but do not necessarily decrease CVD [ 88 ].”
BackgroundThe Dangers of Stopping a Trial Too Early
Briel, M., Bassler, D., Wang, A. T., Guyatt, G. H., & Montori, V. M. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.01412 · Cited by 49
“Implications and Recommendations for Trialists and Consumers Consumers of research evidence should be vigilant that results from trials stopped early for apparent benefit might lead to an overestimated pooled summary effect in metaanalyses, in particular, when the following conditions exist: (1) one or more trials sto…”
BackgroundRosenson, R. S. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 45
Rahman, K., & Fisher, E. A. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00032 · Cited by 53
Uraemic dyslipidaemia revisited: role of high-density lipoprotein
Speer, T., Zewinger, S., & Fliser, D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft080 · Cited by 47
“Treating patients with the CETP inhibitor torcetrapib increased serum HDL-cholesterol levels by ∼72% after 12 months of treatment [57].”
BackgroundPXR agonism decreases plasma HDL levels in ApoE⁎3-Leiden.CETP mice
de Haan, W., der Weij, J. D. V.-V., Mol, I. M., Hoekstra, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M. G., & Rensen, P. C. N. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.12.008 · Cited by 44
“Torcetrapib not only failed to reduce atherosclerosis, as assessed by coronary intima-media thickness (IMT) and intravascular ultrasonography (IVUS) measurements [2–4], but also increased the risk of cardiovascular events and death rate [5].”
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 52
Adipose Modulation of High-Density Lipoprotein Cholesterol
McGillicuddy, F. C., Reilly, M. P., & Rader, D. J. (2011) · Circulation · doi:10.1161/circulationaha.111.058453 · Cited by 45
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 49
Puri, R., Nissen, S. E., Shao, M., Uno, K., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.009 · Cited by 45
Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?
Razavi, A. C., Jain, V., Grandhi, G. R., Patel, P., Karagiannis, A. D., Patel, N. H., Dhindsa, D. S., Liu, C., Desai, S., Almuwaqqat, Z., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad406 · Cited by 50
Very Large Database of Lipids: Rationale and Design
Martin, S. S., Blaha, M. J., Toth, P. P., Joshi, P. H., McEvoy, J. W., Ahmed, H. M., Elshazly, M. B., Swiger, K. J., Michos, E. D., Kwiterovich, P. O., et al. (2013) · Clinical Cardiology · doi:10.1002/clc.22214 · Cited by 42
Cruz, D., Wang, Z., Kibbie, J. J., Modlin, R. L., & Kwon, O. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015254108 · Cited by 43
The end of the road for CETP inhibitors after torcetrapib?
JOY, T. R., & Hegele, R. A. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ac166 · Cited by 46
Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology?
Tardif, J. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.018 · Cited by 43
Self-citation
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.